ERBB2 antibody - 100 µg
Host : Rabbit
Clonality: Polyclonal
Clone:
Isotype: IgG
Immunogen: v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro
glioblastoma derived oncogene homolog(avian)
Purity: ≥95% as determined by SDS-PAGE
Form: Liquid
Molecular weight: 185 kDa
Uniprot: P04626
Gene id: 2064
Background: HER2, also known as ErbB2 and Neu, is a 185-kDa transmembrane glycoprotein that is a member of the epidermal growth factor(EGF) receptor family of receptor tyrosine kinases. It has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Amplification and
or overexpression of HER2 have been reported in numerous cancers, including breast and ovarian tumors. HER2 is a therapeutic target for the treatment of breast cancer and other carcinomas. This antibody raised against a synthesized peptide corresponding to 1237-1255aa of human HER2 recognizes the 185-kDa full-length glycosylated form and other lower molecular-mass forms of HER2, including the truncated form.
Field of research: Signal Transduction, Metabolism, Cardiovascular, Immunology, Cancer, Developmental biology, Stem Cells
Storage conditions: PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20°C for 12 months(Avoid repeated freeze
thaw cycles.)
Applications: ELISA, WB, IHC, FC, IP
Dilution: WB: 1:1000-1:10000; IP: 1:200-1:2000; IHC: 1:50-1:200
Target: ERBB2
Purification: Immunogen affinity purified
Reactivity: Human, Mouse
![]()
Clonality: Polyclonal
Clone:
Isotype: IgG
Immunogen: v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro
glioblastoma derived oncogene homolog(avian)
Purity: ≥95% as determined by SDS-PAGE
Form: Liquid
Molecular weight: 185 kDa
Uniprot: P04626
Gene id: 2064
Background: HER2, also known as ErbB2 and Neu, is a 185-kDa transmembrane glycoprotein that is a member of the epidermal growth factor(EGF) receptor family of receptor tyrosine kinases. It has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Amplification and
or overexpression of HER2 have been reported in numerous cancers, including breast and ovarian tumors. HER2 is a therapeutic target for the treatment of breast cancer and other carcinomas. This antibody raised against a synthesized peptide corresponding to 1237-1255aa of human HER2 recognizes the 185-kDa full-length glycosylated form and other lower molecular-mass forms of HER2, including the truncated form.
Field of research: Signal Transduction, Metabolism, Cardiovascular, Immunology, Cancer, Developmental biology, Stem Cells
Storage conditions: PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20°C for 12 months(Avoid repeated freeze
thaw cycles.)
Applications: ELISA, WB, IHC, FC, IP
Dilution: WB: 1:1000-1:10000; IP: 1:200-1:2000; IHC: 1:50-1:200
Target: ERBB2
Purification: Immunogen affinity purified
Reactivity: Human, Mouse